Director at $CME sells 748 shares in insider transaction

In the latest insider news, it has been reported that Dennis Suskind, a director at the company identified as $CME, recently sold 748 shares of the company, estimated to be worth $224,400, as per a filing with the SEC. This sale amounts to approximately 21.7% of Suskind’s shares of this particular class of stock, leaving them with 2,699 shares of $CME stock post-transaction.

Over the past six months, $CME insiders have conducted a noteworthy 15 trades on the open market. Among these transactions, 4 involved purchases while 11 were sales. Here’s an overview of the recent insider trading activities involving $CME stock:

– TERRENCE A DUFFY, who serves as the Chairman and CEO, made 2 sales of 25,000 shares, generating an estimated $6,738,815.
– SUNIL CUTINHO, the Chief Information Officer, conducted 2 sales of 11,896 shares, resulting in an estimated $3,229,444.
– DEREK SAMMANN, the Senior Managing Director of Global Head Commodities Markets, oversaw 2 sales of 7,200 shares, amounting to approximately $1,984,798.
– HAROLD EUGENE JR. FORD sold 1,000 shares for $263,530.
– DENNIS SUSKIND, in addition to the recent sale, sold 748 shares for $224,400.
– JONATHAN L MARCUS, the Senior Managing Director of General Counsel, conducted 2 sales of 768 shares, tallying up to $200,072.
– WILLIAM R SHEPARD made 4 purchases, buying 536 shares for an estimated $145,679 and made no sales.
– TIMOTHY FRANCIS MCCOURT, the Senior Managing Director of Global Head Equity & FX, sold 379 shares for $98,475.

In terms of hedge fund activity, 838 institutional investors added shares of $CME to their portfolio while 735 decreased their positions in the most recent quarter. Key movements included SANDERS CAPITAL, LLC adding 3,726,755 shares, JPMORGAN CHASE & CO removing 2,744,851 shares, STRIVE ASSET MANAGEMENT, LLC adding 2,355,701 shares, UBS AM, a distinct business unit of UBS Asset Management Americas LLC adding 1,998,425 shares, PRICE T ROWE ASSOCIATES INC /MD/ adding 1,605,469 shares, BLACKROCK, INC. adding 1,222,646 shares, and UBS GROUP AG removing 1,017,014 shares from their portfolio.

Furthermore, data indicates that $CME recorded revenues of $1.6B in Q4 2025, signifying an 8.09% increase from the prior year during the same period.

Considering the involvement of members of Congress in stock trading activities, $CME stock was traded on 5 occasions in the past six months. Out of these transactions, 1 was a purchase while 4 were sales. Representative Julie Johnson made 4 trades, including 1 purchase on 08/11 and 3 sales on 12/18, 11/13, and 08/14 up to $15,000 each, while Representative Val T. Hoyle sold up to $15,000 on 09/23.

Wall Street analysts have also weighed in on $CME, with 4 firms issuing buy ratings and 1 issuing a sell rating. Notable recent ratings include “Overweight” by Piper Sandler on 11/13/2025, “Buy” by Deutsche Bank on 10/23/2025, “Overweight” by Morgan Stanley on 10/23/2025, “Buy” by Citigroup on 09/25/2025, and “Underweight” by JP Morgan on 09/25/2025.

As for price targets, a total of 11 analysts have provided projections for $CME in the last 6 months, with a median target of $307.0. Specific targets include $340.0 by Michael Cyprys from Morgan Stanley, $328.0 by Bill Katz from TD Cowen, $266.0 by Kenneth Worthington from JP Morgan, $302.0 by Ashish Sabadra from RBC Capital, $312.0 by Benjamin Budish from Barclays, $313.0 by Patrick Moley from Piper Sandler, and $300.0 by Brian Bedell from Deutsche Bank.

To conclude, it is worth noting that the content provided should not be construed as financial advice, and readers are encouraged to refer to Quiver Quantitative’s disclaimers for further information.